Square Pharmaceuticals (DHA:SQURPHARMA) Beta: N/A (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:SQURPHARMA Square Pharmaceuticals PLC DHA:SQURPHARMA
94 GF Score
Price BDT214.70
GF Value BDT219.96
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Square Pharmaceuticals Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-09-10), Square Pharmaceuticals's Beta is Not available.

Square Pharmaceuticals  (DHA:SQURPHARMA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Square Pharmaceuticals Beta Related Terms

Square Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Square Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Square Pharmaceuticals Beta Chart

Square Pharmaceuticals Annual Data
Trend Mar16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Square Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DHA:SQURPHARMA
94GF Score
Square Pharmaceuticals PLC DHA:SQURPHARMA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Square Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Square Pharmaceuticals (DHA:SQURPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Square Pharmaceuticals stock appears to be undervalued. The current stock price of BDT214.70 is trading 2.4% below its estimated GF Value™ of BDT219.96. GuruFocus considers Square Pharmaceuticals to be Fairly Valued.

Key valuation signals for DHA:SQURPHARMA:

  • Beta: N/A
  • GF Value™: BDT219.96 vs. price of BDT214.70 (2.4% below fair value)
  • GF Score™: 94/100 with 3 warning signs

No single metric tells the full story. See the DHA:SQURPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Square Pharmaceuticals Business Description

Address Square Centre, 48, Mohakhali Commercial Area, Dhaka, BGD, 1212
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical products, basic chemical products, animal health products, and crop care products, along with the manufacturing, marketing, and distribution of pharmaceutical products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs such as paracetamol, clotrimazole, antiallergic, nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs, and also provides devices such as AnsuPen and AnsuPen Twist.
94GF Score

Get the complete analysis for DHA:SQURPHARMA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT214.70
Price
BDT219.96
GF Value